Aurisco Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	688.91	792.37	769.44	545.84	391.74	444.61
Trading Asset Securities	228.26	161.52	299.83	-	-	-
Cash & Short-Term Investments	917.17	953.9	1,069	545.84	391.74	444.61
Cash Growth	-7.17%	-10.79%	95.89%	39.34%	-11.89%	-21.18%
Accounts Receivable	420.66	434.32	350.87	290.78	222.11	140.72
Other Receivables	3.86	4.02	4.23	8.31	3.9	6.19
Receivables	424.52	438.34	355.11	299.09	226.01	146.91
Inventory	661.59	644.88	589.72	509.8	444.94	326.8
Prepaid Expenses	-	-	-	-	0.17	-
Other Current Assets	23.09	19.48	32.7	11.31	25.5	21.48
Total Current Assets	2,026	2,057	2,047	1,366	1,088	939.8
Property, Plant & Equipment	1,833	1,779	1,497	878.33	674.18	593.26
Long-Term Investments	171.36	166.36	133.47	79.3	55.3	15.3
Other Intangible Assets	159.31	160.37	161.46	121.4	122.71	40.42
Long-Term Deferred Tax Assets	23.61	22.54	15.78	14.29	15.24	8.56
Long-Term Deferred Charges	4.17	4.72	5.32	6.91	11.37	-
Other Long-Term Assets	35.71	32.03	17.41	108.35	68.14	124.09
Total Assets	4,254	4,222	3,877	2,575	2,035	1,721
Accounts Payable	338.35	297.19	297.39	242.53	102.43	128.2
Accrued Expenses	38.7	138.94	121.64	92.89	51.95	40.89
Short-Term Debt	20.02	20.02	20.02	40.04	30	-
Current Portion of Long-Term Debt	24.39	-	-	-	1.3	-
Current Portion of Leases	-	5.87	5.64	5.14	4.93	4.06
Current Income Taxes Payable	21.1	26.02	25	16.64	12.85	8.61
Current Unearned Revenue	8.21	3.06	6.6	22.25	0.98	8.96
Other Current Liabilities	29.23	29.96	55.74	81.53	117.75	2.36
Total Current Liabilities	479.98	521.06	532.04	501.02	322.17	193.08
Long-Term Debt	925.65	917.96	907.09	60.46	4.22	-
Long-Term Leases	23.83	15.12	15.1	11.24	12.23	13.91
Long-Term Unearned Revenue	102.98	105.91	91.57	34.02	7.69	4.53
Long-Term Deferred Tax Liabilities	3.12	4.38	0.1	0.28	4.81	1.92
Total Liabilities	1,536	1,564	1,546	607.03	351.13	213.44
Common Stock	406.18	406.2	406.2	406.2	406.2	401
Additional Paid-In Capital	613.86	613.96	606.5	584.93	553.36	491.73
Retained Earnings	1,637	1,573	1,241	975.92	751.49	592.71
Treasury Stock	-60.03	-55.26	-22.86	-45.72	-57.15	-
Comprehensive Income & Other	121.3	119.51	100.34	46.25	22.28	20.8
Total Common Equity	2,718	2,658	2,332	1,968	1,676	1,506
Minority Interest	-	-	-	-	7.99	1.75
Shareholders' Equity	2,718	2,658	2,332	1,968	1,684	1,508
Total Liabilities & Equity	4,254	4,222	3,877	2,575	2,035	1,721
Total Debt	993.88	958.97	947.85	116.88	52.69	17.97
Net Cash (Debt)	-76.71	-5.07	121.42	428.95	339.05	426.64
Net Cash Growth	-	-	-71.69%	26.52%	-20.53%	-24.37%
Net Cash Per Share	-0.19	-0.01	0.30	1.05	0.84	1.06
Filing Date Shares Outstanding	399.54	403.41	406.2	406.2	406.2	401
Total Common Shares Outstanding	399.54	406.2	406.2	406.2	406.2	401
Working Capital	1,546	1,536	1,515	865.02	766.19	746.72
Book Value Per Share	6.80	6.54	5.74	4.84	4.13	3.76
Tangible Book Value	2,559	2,497	2,170	1,846	1,553	1,466
Tangible Book Value Per Share	6.41	6.15	5.34	4.55	3.82	3.66
Buildings	-	621.3	291.81	291.85	289.74	283.37
Machinery	-	1,446	735.79	640.39	587.27	485.03
Construction In Progress	-	217.39	869.74	280.64	79.93	47.83

Source: S&P Global Market Intelligence. Standard template. Financial Sources.